Charles River has announced a $212 million purchase of British company Celsis International. The company specializes in providing systems that are used to detect harmful contaminants in substances ranging from prescription drugs to consumer beverages.
The acquisition of Celsis International Ltd. complements Charles River Endotoxin and Microbial Detection’s (EMD) position as a leading provider of rapid endotoxin testing and bacterial identification for biopharmaceutical manufacturing, and creates the most comprehensive solution for rapid quality control testing of biopharmaceutical and consumer products.
Charles River announced that it has entered into a definitive agreement to acquire Celsis International Ltd. for $212 million in cash, subject to customary closing adjustments.
Charles River is absorbing Celsis, a Chicago-headquartered company that tests drugs and consumer products for contamination. Celsis works with pharma, beauty companies and the food industry, touting itself as a provider of rapid testing systems that allow clients to quickly get their products onto the market.
Charles River Labs announced Thursday that it had signed an agreement to acquire the bacteria detection company Celsis International Ltd. for $212 million. This acquisition will strengthen the Wilmington company’s market position in testing the safety of drugs and consumer products.
Foster Jordan, Corporate Senior Vice President of the Endotoxin and Microbial Detection division, discusses the process of detecting, quantifying and identifying microorganisms in products and facilities more rapidly, objectively and efficiently than the traditional method of growing microorganisms in culture media.
G protein coupled receptors (GPCRs) are essential drug targets for therapeutic intervention due to their integral roles in a plethora of fundamental signal transduction pathways.
Carl Craig, Corporate Vice President Global Bacterial Identification Services and EMD Product Distribution, discusses Charles River’s leadership position in the Microbiology QC testing market.
Foster Jordan, Corporate Senior Vice President of the Endotoxin and Microbial Detection division speaks with Outsourcing-Pharma.com on how bacterial testing is moving from the lab to the manufacturing floor.
Five toxicologic pathologists offer their perspectives on the benefits and challenges of forging a career in toxicology.